Published in Int J Cancer on December 01, 2010
Microsatellite instability and BRAF mutation testing in colorectal cancer prognostication. J Natl Cancer Inst (2013) 4.37
Colorectal cancer molecular biology moves into clinical practice. Gut (2010) 2.32
Specific mutations in KRAS codons 12 and 13, and patient prognosis in 1075 BRAF wild-type colorectal cancers. Clin Cancer Res (2012) 1.95
Tumor TP53 expression status, body mass index and prognosis in colorectal cancer. Int J Cancer (2011) 1.12
KRAS mutation testing in metastatic colorectal cancer. World J Gastroenterol (2012) 1.11
KRAS codon 12 and 13 mutations in relation to disease-free survival in BRAF-wild-type stage III colon cancers from an adjuvant chemotherapy trial (N0147 alliance). Clin Cancer Res (2014) 1.08
Prognostic and predictive roles of KRAS mutation in colorectal cancer. Int J Mol Sci (2012) 1.07
BRAFV600E immunohistochemistry in conjunction with mismatch repair status predicts survival in patients with colorectal cancer. Mod Pathol (2013) 0.96
Sex differences in the prognostic significance of KRAS codons 12 and 13, and BRAF mutations in colorectal cancer: a cohort study. Biol Sex Differ (2013) 0.93
Associations of anthropometric factors with KRAS and BRAF mutation status of primary colorectal cancer in men and women: a cohort study. PLoS One (2014) 0.92
Sessile serrated adenoma shares similar genetic and epigenetic features with microsatellite unstable colon cancer in a location-dependent manner. Exp Ther Med (2011) 0.89
Colorectal carcinomas with KRAS codon 12 mutation are associated with more advanced tumor stages. BMC Cancer (2015) 0.87
Clinical utility of KRAS and BRAF mutations in a cohort of patients with colorectal neoplasms submitted for microsatellite instability testing. Clin Colorectal Cancer (2013) 0.85
Cathepsin B expression and survival in colon cancer: implications for molecular detection of neoplasia. Cancer Epidemiol Biomarkers Prev (2010) 0.85
Molecular alterations and biomarkers in colorectal cancer. Toxicol Pathol (2013) 0.83
An appraisal of lymph node ratio in colon and rectal cancer: not one size fits all. Int J Colorectal Dis (2013) 0.83
Distinct Clinicopathological Patterns of Mismatch Repair Status in Colorectal Cancer Stratified by KRAS Mutations. PLoS One (2015) 0.81
Molecular pathological epidemiology of colorectal cancer in Chinese patients with KRAS and BRAF mutations. Oncotarget (2015) 0.79
Prognostic role of KRAS mutations in Sardinian patients with colorectal carcinoma. Oncol Lett (2016) 0.76
Neuroendocrine and squamous colonic composite carcinoma: case report with molecular analysis. World J Gastroenterol (2011) 0.75
Prognostic impact of KRAS, NRAS, BRAF, and PIK3CA mutations in primary colorectal carcinomas: a population-based study. J Transl Med (2016) 0.75
FAT1: a potential target for monoclonal antibody therapy in colon cancer. Br J Cancer (2016) 0.75
Prognostic value of KRAS codon 13 gene mutation for overall survival in colorectal cancer: Direct and indirect comparison meta-analysis. Medicine (Baltimore) (2017) 0.75
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol (2010) 13.25
Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol (2008) 11.73
Interferon signaling and treatment outcome in chronic hepatitis C. Proc Natl Acad Sci U S A (2008) 8.56
Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA (2010) 8.21
IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors. Hum Mutat (2009) 7.68
Estrogen receptor alpha (ESR1) gene amplification is frequent in breast cancer. Nat Genet (2007) 5.19
Frequent EpCam protein expression in human carcinomas. Hum Pathol (2004) 4.94
Multiple colorectal adenomas, classic adenomatous polyposis, and germ-line mutations in MYH. N Engl J Med (2003) 4.88
PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. Cancer Res (2009) 4.82
Common genetic variants at the CRAC1 (HMPS) locus on chromosome 15q13.3 influence colorectal cancer risk. Nat Genet (2007) 3.93
Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients. J Clin Oncol (2009) 3.57
Towards the introduction of the 'Immunoscore' in the classification of malignant tumours. J Pathol (2014) 3.21
Dysfunctional interaction of C/EBPalpha and the glucocorticoid receptor in asthmatic bronchial smooth-muscle cells. N Engl J Med (2004) 3.13
Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus. J Clin Invest (2010) 3.11
Cancer classification using the Immunoscore: a worldwide task force. J Transl Med (2012) 2.88
Revised guidelines for the clinical management of Lynch syndrome (HNPCC): recommendations by a group of European experts. Gut (2013) 2.86
Interferon-induced gene expression is a stronger predictor of treatment response than IL28B genotype in patients with hepatitis C. Gastroenterology (2010) 2.68
SKIP SEQUENCING: A DECISION PROBLEM IN QUESTIONNAIRE DESIGN. Ann Appl Stat (2008) 2.60
Nonsense-mediated decay microarray analysis identifies mutations of EPHB2 in human prostate cancer. Nat Genet (2004) 2.44
Prevalence of the alternative lengthening of telomeres telomere maintenance mechanism in human cancer subtypes. Am J Pathol (2011) 2.41
Prevalence of KIT expression in human tumors. J Clin Oncol (2004) 2.40
Impairment of hepatic growth hormone and glucocorticoid receptor signaling causes steatosis and hepatocellular carcinoma in mice. Hepatology (2011) 2.33
Genomic instability--the engine of tumorigenesis? Nat Rev Cancer (2003) 2.27
Long noncoding RNA HOTTIP/HOXA13 expression is associated with disease progression and predicts outcome in hepatocellular carcinoma patients. Hepatology (2014) 2.27
Increased detection sensitivity for KRAS mutations enhances the prediction of anti-EGFR monoclonal antibody resistance in metastatic colorectal cancer. Clin Cancer Res (2011) 2.27
Interleukin 6 is important for survival after partial hepatectomy in mice. Hepatology (2003) 2.27
Rounding Probabilistic Expectations in Surveys. J Bus Econ Stat (2010) 2.19
Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer. PLoS One (2009) 2.18
Selecting immunohistochemical cut-off scores for novel biomarkers of progression and survival in colorectal cancer. J Clin Pathol (2006) 2.17
Clinicopathological and protein characterization of BRAF- and K-RAS-mutated colorectal cancer and implications for prognosis. Int J Cancer (2010) 2.08
Hepatic mTORC2 activates glycolysis and lipogenesis through Akt, glucokinase, and SREBP1c. Cell Metab (2012) 2.03
Somatic mutations activating STAT3 in human inflammatory hepatocellular adenomas. J Exp Med (2011) 2.03
The application of markers (HSP70 GPC3 and GS) in liver biopsies is useful for detection of hepatocellular carcinoma. J Hepatol (2008) 2.03
World Allergy Organization (WAO) Diagnosis and Rationale for Action against Cow's Milk Allergy (DRACMA) Guidelines. World Allergy Organ J (2010) 2.01
Immunohistochemical analysis reveals high frequency of PMS2 defects in colorectal cancer. Gastroenterology (2005) 1.96
High frequency of tumor-infiltrating FOXP3(+) regulatory T cells predicts improved survival in mismatch repair-proficient colorectal cancer patients. Int J Cancer (2010) 1.96
Epithelial mesenchymal transition and tumor budding in aggressive colorectal cancer: tumor budding as oncotarget. Oncotarget (2010) 1.88
Expression and functional role of a transcribed noncoding RNA with an ultraconserved element in hepatocellular carcinoma. Proc Natl Acad Sci U S A (2010) 1.87
Diagnostic value of HSP70, glypican 3, and glutamine synthetase in hepatocellular nodules in cirrhosis. Hepatology (2007) 1.81
High incidence of EMMPRIN expression in human tumors. Int J Cancer (2006) 1.74
Inducible inactivation of Notch1 causes nodular regenerative hyperplasia in mice. Hepatology (2005) 1.73
Alterations of RB1, p53 and Wnt pathways in hepatocellular carcinomas associated with hepatitis C, hepatitis B and alcoholic liver cirrhosis. Int J Cancer (2003) 1.67
Expression of hepatitis c virus proteins inhibits interferon alpha signaling in the liver of transgenic mice. Gastroenterology (2003) 1.66
Constitutive Notch2 signaling induces hepatic tumors in mice. Hepatology (2013) 1.65
Mutational profile of GNAQQ209 in human tumors. PLoS One (2009) 1.62
AMACR expression in colorectal cancer is associated with left-sided tumor localization. Virchows Arch (2008) 1.61
Methylation-induced G(2)/M arrest requires a full complement of the mismatch repair protein hMLH1. EMBO J (2003) 1.60
World Allergy Organization (WAO) Diagnosis and Rationale for Action against Cow's Milk Allergy (DRACMA) Guidelines. Pediatr Allergy Immunol (2010) 1.58
BRAF alterations are associated with complex mutational profiles in malignant melanoma. Oncogene (2004) 1.58
Pegylated IFN-α regulates hepatic gene expression through transient Jak/STAT activation. J Clin Invest (2014) 1.54
Expression of CEACAM6 in resectable colorectal cancer: a factor of independent prognostic significance. J Clin Oncol (2003) 1.49
aCGH on chorionic villi mirrors the complexity of fetoplacental mosaicism in prenatal diagnosis. Prenat Diagn (2011) 1.49
KRAS and BRAF mutations predict primary resistance to imatinib in gastrointestinal stromal tumors. Clin Cancer Res (2012) 1.49
Quantitative 1-step DNA methylation analysis with native genomic DNA as template. Clin Chem (2010) 1.48
HER2 gene status in primary breast cancers and matched distant metastases. Breast Cancer Res (2007) 1.45
The homeobox intestinal differentiation factor CDX2 is selectively expressed in gastrointestinal adenocarcinomas. Mod Pathol (2004) 1.44
DNA fingerprinting of glioma cell lines and considerations on similarity measurements. Neuro Oncol (2012) 1.44
Breast cancer resistance protein and P-glycoprotein expression in patients with newly diagnosed and therapy-refractory ulcerative colitis compared with healthy controls. Digestion (2008) 1.43
Calcifying fibrous tumor of the stomach: clinicopathologic and molecular study of seven cases with literature review and reappraisal of histogenesis. Am J Surg Pathol (2010) 1.43
ALK testing in lung adenocarcinoma: technical aspects to improve FISH evaluation in daily practice. J Thorac Oncol (2015) 1.42
New GATA1 mutation in codon 2 leads to the earliest known premature stop codon in transient myeloproliferative disorder. Blood (2009) 1.42
Is the improved prognosis of p16 positive oropharyngeal squamous cell carcinoma dependent of the treatment modality? Int J Cancer (2010) 1.41
KRAS mutational test for metastatic colorectal cancer patients: not just a technical problem. Expert Rev Mol Diagn (2012) 1.41
Differential diagnosis of IgE-mediated allergy in young children with wheezing or eczema symptoms using a single blood test. Ann Allergy Asthma Immunol (2004) 1.39
Phosphatase protein homologue to tensin expression and phosphatidylinositol-3 phosphate kinase mutations in colorectal cancer. Cancer Res (2005) 1.38
Proposal for a 10-high-power-fields scoring method for the assessment of tumor budding in colorectal cancer. Mod Pathol (2012) 1.38
The additional facet of immunoscore: immunoprofiling as a possible predictive tool for cancer treatment. J Transl Med (2013) 1.31
PIK3CA cancer mutations display gender and tissue specificity patterns. Hum Mutat (2008) 1.29
Leiden Open Variation Database of the MUTYH gene. Hum Mutat (2010) 1.28
Prognostic significance of CD8+ T lymphocytes in breast cancer depends upon both oestrogen receptor status and histological grade. Histopathology (2011) 1.26
HER2, TOP2A, CCND1, EGFR and C-MYC oncogene amplification in colorectal cancer. J Clin Pathol (2006) 1.24
Reconstitution of human telomerase reverse transcriptase expression rescues colorectal carcinoma cells from in vitro senescence: evidence against immortality as a constitutive trait of tumor cells. Cancer Res (2005) 1.24
Comprehensive analysis of CpG island methylator phenotype (CIMP)-high, -low, and -negative colorectal cancers based on protein marker expression and molecular features. J Pathol (2011) 1.24
Diagnosis and Rationale for Action Against Cow's Milk Allergy (DRACMA): a summary report. J Allergy Clin Immunol (2010) 1.24
Node-negative colorectal cancer at high risk of distant metastasis identified by combined analysis of lymph node status, vascular invasion, and Raf-1 kinase inhibitor protein expression. Clin Cancer Res (2008) 1.23
Loss of raf-1 kinase inhibitor protein expression is associated with tumor progression and metastasis in colorectal cancer. Am J Clin Pathol (2007) 1.22
Loss of p16 protein defines high-risk patients with gastrointestinal stromal tumors: a tissue microarray study. Clin Cancer Res (2005) 1.22
Cyclooxygenase-2 and platelet-derived growth factor receptors as potential targets in treating aggressive fibromatosis. Clin Cancer Res (2007) 1.21
Loss of the CBX7 protein expression correlates with a more aggressive phenotype in pancreatic cancer. Eur J Cancer (2010) 1.21
EphB2 expression across 138 human tumor types in a tissue microarray: high levels of expression in gastrointestinal cancers. Clin Cancer Res (2005) 1.21
Interferon stimulated gene 15 constitutively produced by melanoma cells induces e-cadherin expression on human dendritic cells. Cancer Res (2002) 1.21
Refining the relation between 'first hits' and 'second hits' at the APC locus: the 'loose fit' model and evidence for differences in somatic mutation spectra among patients. Oncogene (2003) 1.20
VHL-gene deletion in single renal tubular epithelial cells and renal tubular cysts: further evidence for a cyst-dependent progression pathway of clear cell renal carcinoma in von Hippel-Lindau disease. Am J Surg Pathol (2010) 1.19
Systematic analysis of proteins from different signaling pathways in the tumor center and the invasive front of colorectal cancer. Hum Pathol (2011) 1.18
Germ line mutations of mismatch repair genes in hereditary nonpolyposis colorectal cancer patients with small bowel cancer: International Society for Gastrointestinal Hereditary Tumours Collaborative Study. Clin Cancer Res (2006) 1.18
SMAD7 is a prognostic marker in patients with colorectal cancer. Int J Cancer (2003) 1.18